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Mutations in Helicobacter pylori porD and oorD Genes May Contribute to 
Furazolidone Resistance
Aim To determine the rate of furazolidone resistance of Helicobacter 
pylori (H. pylori) isolated from gastric biopsy specimens and to ex-
plore the relationship between genetic mutations in porD and oorD 
genes of H. pylori and its resistance to the antibiotic.
Methods Gastric biopsy was performed in 83 adult patients aged 31-
77 years with gastric complaints. H. pylori was isolated from biopsy 
specimens of 46 patients. E-test and 2-fold agar dilution method 
were used to determine the rate of H. pylori resistance to furazoli-
done. The genes porD and oorD from susceptible and resistant iso-
lates were amplified by polymerase chain reaction (PCR), and their 
PCR products were sequenced.
Results Resistance to furazolidone was found in 8.7% of H. pylori 
isolates and 6 mutations were detected in porD and oorD genes of the 
resistant isolates. Three mutations – G353A, A356G, and C357T 
– occurred in porD and the other mutations – A041G, A122G, 
C349A(G) – occurred in oorD genes.
Conclusions Changes in 6 amino acids may be associated with the 
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Helicobacter pylori (H. pylori), a microaerophilic, 
gram-negative, spiral-shaped bacterium, infects 
the stomach of more than half of the human 
population worldwide (1). The prevalence of H. 
pylori infection greatly varies (2). Eighty percent 
of middle-aged adults are infected with H. pylo-
ri in developing countries, but only 20%-50% in 
developed countries (3). The organism has been 
accepted as the etiological agent of many diges-
tive diseases (4). Clinical experience has demon-
strated that H. pylori infection is not easy to cure. 
The primary obstacles to successful treatment are 
lack of patient compliance with the drug regi-
mens and the development of antibiotic resis-
tance (5).
Metronidazole, a prodrug that can steril-
ize the gastric epithelium by inducing H. pylori 
DNA strand breakage, helix destabilization, and 
unwinding (6), remains a major component of 
new triple and quadruple therapies for successful 
treatment for H. pylori infection (7). Monother-
apy with metronidazole results in the develop-
ment of metronidazole resistance, found in more 
than 50% of H. pylori isolates. Furthermore, 
metronidazole is also highly mutagenic, and its 
use may result in the generation of resistance to 
other clinically used antibiotics, such as clarithro-
mycin (8).
The other prodrug, furazolidone, used for 
the treatment of H. pylori infection (9), can also 
induce the resistance in H. pylori but the mech-
anism of this resistance is still not clear. Since 
bioactivity of furazolidone is similar to that of 
metronidazole, Kwon et al (10) presumed that 
por and oor genetic mutations of H. pylori were 
involved in furazolidone resistance.
Our aim was to determine the resistance rate 
of H.pylori to furazolidone in isolates from gas-
tric biopsy specimens taken from the patients 
from Zhenjiang, Jiangsu province of China, and 
establish the relationship between possible muta-




A total of 83 patients (48 men and 35 wom-
en) aged between 31 and 77 years, who lived in 
Zhenjiang, were enrolled in the study because of 
gastric complaints. All patients underwent up-
per gastrointestinal endoscopy and gastric biop-
sy. Three biopsy specimens were taken from the 
antrum of the gastric body or the duodenal mu-
cosa and processed within 3 hours. Two of the 
samples were used for the rapid detection of ure-
ase activity and pathologic diagnosis, and anoth-
er one was used for biopsy culture. Most patients 
(n = 74) were diagnosed with gastric ulcer, 8 had 
gastritis, and one patient was diagnosed with gas-
tric cancer. Of 83 patients, 68 had previously re-
ceived eradication therapy with metronidazole 
and clarithromycin.
Biopsy culture
Gastric biopsy samples including NCTC11637 
were routinely cultured on Columbia blood agar 
plates (Oxoid Ltd, London, England) contain-
ing 5% fresh sheep blood under microaerobic 
conditions at 37° for 3 days. Strains were iden-
tified according to colony morphology, Gram 
stain, urease, catalase, oxidase, and biochemical 
properties (11).
Table 1. Polymerase chain reaction (PCR) primers used to amplify portions of genes of H. pylori isolated from gastric biopsy specimens 
from 46 patients
Primer pair Encoded protein (gene) Nucleotide sequences PCR fragment size (bp)
POR-A Pyruvate oxidoreductase (porD) 5′-GCAAGAAGTCATTGACGC-3′ 592
POR-B 5′-GGGGTGATAGGATAGGCT-3′
OOR-A 2-oxoglutarate oxidoreductase (oorD) 5-TTTAGCACAAAGGAGAATG-3′ 458
OOR-B 5′-AACTTGGCGTAATAGGAT-3′
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Minimal inhibitory concentration of furazolidone
The minimal inhibitory concentration (MIC) 
for isolated H. pylori strains was defined as the 
concentration of a drug needed to inhibit 50% of 
H. pylori growth and determined by 2-fold agar 
dilution and E-test. Agar dilution plates were 
prepared with Jeller-Hinton (MH) agar as the 
base medium. Sheep blood was added to the MH 
base medium at a concentration of 5%. Furazoli-
done solution was prepared in sterile distilled wa-
ter and was added to 5% sheep blood-MH base 
medium to achieve serial concentration of 0.5-
3.0 µg/mL of furazolidone per mL (12). Fresh 
H. pylori isolates (3 days culture) were prepared 
in saline to an optical density. With a Steers-type 
replicating device, 1-2 mL of the adjusted inoc-
ulum was delivered to the agar plates. All plates 
were incubated under microaerobic conditions 
for 3 days. The MIC was defined as the lowest 
concentration of furazolidone that completely 
inhibited the growth of the inoculum (13).
Isolation of DNA
H. pylori genomic DNAs were isolated as de-
scribed previously by Majewski and Goodwin 
(14). In brief, H. pylori was diluted in phosphate-
buffered saline (PBS), vortexed, and centrifuged 
at 13000 × g for 5 minutes. The supernatant was 
discarded, and the pellet was resuspended in 100 
μL of Tris-EDTA (EDTA) buffer (pH 8.0, 1 
mmol/L Tris-HCl, and 0.1 mmol/L EDTA), 
500 μL of guanidine thiocyanate, 0.5 mol/L 
EDTA, pH 8.0, and 10% sodium lauryl sulfate 
(GES). The suspension was incubated for 5 min-
utes at room temperature, then placed on ice for 
2 minutes. The mixture was added into 250 μL 
of ammonium acetate (7.5 mol/L) and placed on 
ice for 5 minutes. Then, 650 μL of chloroform so-
lution was added and the mixture vortexed. Af-
ter centrifugation at 13 000 × g for 5-minute, the 
supernatant was transferred into a new tube (cal-
culate volume), diluted in 0.54 × dimethyl-carbi-
nol, vortexed, and left at room temperature for 5 
minutes. Centrifugation at 13 000 × g for 5 min-
utes was repeated and the supernatant discarded. 
The pellet was washed twice with 500 mL of 70% 
alcohol. The DNA samples were stored at 4°C in 
100-200 μL of Tris-EDTA buffer until use.
Polymerase chain reaction amplification of porD 
and oorD
The porD and oorD genes were amplified by poly-
merase chain reaction (PCR) in a DNA ther-
mal cycler. The amplified fragments of porD and 
oorD had 592 bp and 458 bp, respectively (Table 
1). The PCR conditions consisted of 1 cycle at 
95°C for 5 minutes followed by 30 cycles of de-
naturation at 95°C for 30 s, annealing at 48°C 
(porD) or 44°C (oorD) for 45 s, and extension at 
72°C for 1 minute. The final step was extension 
at 72°C for 10 minutes. The PCR products were 
purified and sequenced (Shanghai GeneCore 
BioTechnologies Co. Ltd, Shanghai, China). The 
sequences were analyzed with the Blast engine 
for the alignment of two given sequences (http://
www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi) 
and ExPASy for the translation of a nucleotide 




H. pylori was isolated from gastric biopsy spec-
imens from 46 patients of 83 included in the 
study. Of 46 H. pylori isolates, 42 were suscep-
Figure 1. Minimum inhibitory concentration of furazolidone for Heli-
cobacter pylori isolates from gastric biopsy specimens obtained from 
46 patients.
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tible to furazolidone at MIC <2 µg/mL, where-
as the remaining 4 were resistant to the drug at 
MIC >2 µg/mL. Furazolidone resistance was 
found in patients who had been treated previous-
ly with metronidazole. The similar results were 
found by using E-test. In addition, we found the 
resistance of 4 isolates at a low level of furazoli-
done (2-3 µg/mL) (Figure 1).
Amplicons and sequence analysis
The porD and oorD amplicons had 592 bp and 
458 bp, respectively (Figure 2). By sequenc-
ing porD and oorD, we detected 6 amino acid 
changes in resistant isolates. Among these muta-
tions, three (G353A, A356G, and C357T) oc-
curred in porD gene and these mutations led to 
three amino acid changes; Glu→ Asp, Ala→Thr, 
and Thr→Val, respectively (Figure 3). The other 
three – A041G, A122G, and C349A(G) – were 
found in oorD gene, causing three amino acid 
substitutions: Thr→Ala, Ile→Val and Asn→
Lys, respectively (Figure 4). In addition, a syn-
onymous substitution C357G at position 357 
in porD was detected in intermediate susceptible 
strains to furazolidone (MIC = 1-2 µg/mL) (Fig-
ure 3). This substitution might suggest a transi-
tional form of H. pylori from a susceptive one to 
that resistant to furazolidone.
Discussion
Our results show that the mutations of porD and 
oorD in H. pylori may be associated with resis-
tance to furazolidone. The physiology and me-
tabolism of H. pylori are not well understood 
(15). H. pylori has enzymes of the Entner-Dou-
doroff and pentose-phosphate pathways (16). 
However, the major routes for the generation of 
acetyl coenzyme A (acetyl-CoA) and succinyl-
CoA are via pyruvate:flavodoxin oxidoreduc-
Figure 2. Agarose gel electropherogram of porD (A) and oorD (B). A. Markers (from the left): NCTC11637, ZJ0021, ZJ0023, ZJ0027, ZJ0024, 
ZJ0021, and negative control. B. Markers (from the left): NCTC11637, ZJ0021, ZJ0024, ZJ0003, and negative control.
Figure 3. Analysis of porD mutations from furazolidone-resistant strains of Helicobacter pylori showed that 353 glutamate was replaced by aspartate, 
356 alanine by threonine, and 357 threonine by valine.
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tase (POR) and 2-oxoglutarate:acceptor oxidore-
ductase (OOR), respectively. These two electron 
acceptors may be ferredoxin (Fd) or flavodox-
in (FldA). Both porD and oorD encode inte-
gral ferredoxin-like subunits (17). Furazolidone 
is a nitrofuran antibiotic. For nitrofurans, the 
spectrum of bioactivity and the mechanism of ac-
tivation mainly depend on the redox potential of 
the 5-nitro groups. Furazolidone shows relative-
ly high redox potentials (-250 to -270 mA) and 
is reductively activated by a wide range of nitro-
reductases (18). Putative H. pylori nitroreductas-
es include FdxB, FrxA, RdxA, OorD, and PorD. 
Kwon DH et al (19) found that the inactivation 
of fdxB, frxA, and rdxA genes did not cause a le-
thal effect on H. pylori, but that both porD and 
oorD seem to be necessary for survival of H. py-
lori. They also discovered that RdxA, FrxA, and 
FdxB could not deoxidize furazolidone. The 
rdxA, frxA, and fdxB genes, which were knocked 
out, did not result in the resistance of H. pylori 
to furazolidone (10). Therefore, Kwon et al (19) 
suggested that por and oor genes might be crucial 
for the resistance of H. pylori to furazolidone.
The extensive use of furazolidone results in 
increasing resistance rate of H. pylori. In addi-
tion, the resistance rate seems to vary from one 
geographic region to another (20). For exam-
ple, Shan et al (21) reported H. pylori resistance 
rate to furazolidone of up to 40% in Shanghai, 
in Southeastern China. On the other hand, Liu 
et al (22) reported that all H. pylori isolates were 
susceptible to furazolidone in Shijiazhuang city, 
in Northern China. Our results showed that 
H. pylori resistance rate was 8.7% in Zhenjiang, 
which is located in the south of Yangtze Riv-
er, supporting the previous observation of geo-
graphic variations in H. pylori resistance rate. 
The major reasons for this difference may be due 
to different lifestyle in different regions. For ex-
ample, people living in southeast China eat lot of 
fish. Since furazolidone is often used as an anti-
septic in fishponds, it can lead to the accumula-
tion of the drug in fish and increased exposure of 
the population living in that part of China, lead-
ing to the observed high H. pylori resistance rate 
to furazolidone.
Sisson et al (23) discovered that partially in-
hibitory (near MIC) concentrations of furazoli-
done were somewhat mutagenic for H. pylori, 
suggesting that the porD and oorD mutations of 
resistant and intermediately susceptible strains 
might have relations with furazolidone bioactivi-
ty. In the present study, we found that both porD 
and oorD of resistant strains had three mutations 
each. These mutations in both genes may con-
tribute to the resistance of H. pylori to furazoli-
done, which is a findind consistent with observa-
tions by Kwan et al (19).
In conclusion, we found a relatively high rate 
of H. pylori resistance to antibiotics in in Zhen-
jiang, China. This finding is in accordance with 
Figure 4. Analysis of oorD mutations from furazolidone-resistant strains of Helicobacter pylori showed that 041 threonine was replaced by alanine, 
122 isoleucine by valine, and 349 asparagine by lysine.
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previous observations that H. pylori resistance 
significantly varies with geographic region in 
China. Furthermore, our results showed the as-
sociation between mutations in porD and oorD 
genes of H. pylori and its resistance to furazoli-
done. These findings may provide useful infor-
mation to a clinician administering antibiotics 
for the treatment of H. pylori infection. Howev-
er, further research is needed to understand the 
exact resistance mechanism of H. pylori to fura-
zolidone.
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